These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. Norrby SR; Newell PA; Faulkner KL; Lesky W J Antimicrob Chemother; 1995 Jul; 36 Suppl A():207-23. PubMed ID: 8543496 [TBL] [Abstract][Full Text] [Related]
5. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Balfour JA; Bryson HM; Brogden RN Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235 [TBL] [Abstract][Full Text] [Related]
7. Carbapenems: monotherapy in intra-abdominal sepsis. Wilson SE Scand J Infect Dis Suppl; 1995; 96():28-33. PubMed ID: 7652500 [TBL] [Abstract][Full Text] [Related]
8. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Tellado JM; Wilson SE Surg Infect (Larchmt); 2005; 6(3):329-43. PubMed ID: 16201943 [TBL] [Abstract][Full Text] [Related]
9. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Hellinger WC; Brewer NS Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472 [TBL] [Abstract][Full Text] [Related]
10. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Ong CT; Kuti JL; Nicolau DP; Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606 [TBL] [Abstract][Full Text] [Related]
12. Imipenem/cilastatin: the first carbapenem antibiotic. Lyon JA Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385 [TBL] [Abstract][Full Text] [Related]
14. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044 [TBL] [Abstract][Full Text] [Related]
15. Safety of imipenem/cilastatin in neurocritical care patients. Hoffman J; Trimble J; Brophy GM Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700 [TBL] [Abstract][Full Text] [Related]
16. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem. Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653 [TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of carbapenem antibacterials. Norrby SR Drug Saf; 1996 Aug; 15(2):87-90. PubMed ID: 8884160 [TBL] [Abstract][Full Text] [Related]
18. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group. Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488 [TBL] [Abstract][Full Text] [Related]
19. Carbapenems in serious infections: a risk-benefit assessment. Norrby SR Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843 [TBL] [Abstract][Full Text] [Related]
20. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group. Romanelli G; Cravarezza P J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]